Mazen M Dimachkie

List of Publications by Year
in descending order

143	6,279	66343	82547
papers	citations	42 h-index	72 g-index

149	149	149	6499
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
2	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	36
3	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	1.5	7
4	Measuring change in inclusion body myositis: clinical assessments versus imaging. Clinical and Experimental Rheumatology, 2022, 40, 404-413.	0.8	6
5	Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis. Clinical and Experimental Rheumatology, 2022, 40, 384-393.	0.8	8
6	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	1
7	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.1	22
8	Openâ€label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, , .	2.2	1
9	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS).. Clinical and Experimental Rheumatology, 2022, 40, 214-218.	0.8	0
10	Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis.. Clinical and Experimental Rheumatology, 2022, 40, 384-393.	0.8	0
11	Measuring change in inclusion body myositis: clinical assessments versus imaging.. Clinical and Experimental Rheumatology, 2022, 40, 404-413.	0.8	0
12	<scp>Nonâ€dystrophic</scp> myotonia: 2â€year clinical and patient reported outcomes. Muscle and Nerve, 2022, 66, 148-158.	2.2	3
13	Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease. Neurology, 2022, 99, .	1.1	16
14	Is it really myositis? Mimics and pitfalls. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101764.	3.3	5
15	Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS). JAMA Neurology, 2021, 78, 68.	9.0	23
16	Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (â€œProDERM Studyâ€). Medicine (United States), 2021, 100, e23677.	1.0	35
17	Quantifying Treatment-Related Fluctuations in CIDP. Neurology, 2021, 96, e1876-e1886.	1.1	15
18	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis. Neurology, 2021, 96, e1595-e1607.	1.1	25

#	Article	IF	Citations
19	Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2021, 64, 243-254.	2.2	7
20	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536.	10.2	194
21	Teaching NeuroImage: Immune Checkpoint Inhibitorâ€"Related Fasciitis and Myositis With Perifascicular Atrophy. Neurology, 2021, 97, 1049-1050.	1.1	1
22	Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors. European Neurology, 2021, 84, 43-48.	1.4	11
23	Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology, The, 2021, 20, 1012-1026.	10.2	59
24	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 15-23.	1.7	12
25	Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part I: Traditional agents. Muscle and Nerve, 2020, 61, 5-16.	2.2	7
26	Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents. Muscle and Nerve, 2020, 61, 17-25.	2.2	14
27	Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2020, 61, 575-579.	2.2	41
28	Magnetic resonance imaging correlates with electrical impedance myography in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2020, 61, 644-649.	2.2	10
29	Transthyretin Familial Amyloid Polyneuropathy Mimicking Chronic Inflammatory Demyelinating Polyneuropathy. RRNMF Neuromuscular Journal, 2020, 1, 26-31.	0.1	0
30	Rhabdomyolysis and COVID-19 Infection: Is It Due to Statin Use or Anti-TIF1-γ Antibodies?. RRNMF Neuromuscular Journal, 2020, 1, 22-25.	0.1	1
31	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	1.9	12
32	Amyloid Myopathy as an Inclusion Body Myositis Mimic. RRNMF Neuromuscular Journal, 2020, 1, 28-32.	0.1	3
33	Clinical features of <scp>LRP4</scp>/agrinâ€antibodyâ€"positive myasthenia gravis: A multicenter study. Muscle and Nerve, 2020, 62, 333-343.	2.2	46
34	Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets. Journal of Visualized Experiments, 2020, , .	0.3	4
35	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 582.	9.0	126
36	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€"Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6

#	Article	IF	Citations
37	Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial. Kansas Journal of Medicine, 2020, 13, 10-13.	0.4	0
38	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
39	Peripheral Neuropathy Research Registry: A prospective cohort. Journal of the Peripheral Nervous System, 2019, 24, 39-47.	3.1	10
40	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
41	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	3.1	13
42	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
43	Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. Muscle and Nerve, 2019, 60, 161-168.	2.2	8
44	NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. Molecular Genetics and Metabolism, 2019, 126, S115-S116.	1.1	0
45	Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective. Journal of Neuroscience Nursing, 2019, 51, 198-203.	1.1	3
46	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve, 2019, 59, 201-207.	2.2	35
47	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle and Nerve, 2019, 59, 404-410.	2.2	56
48	Approach to Muscle and Neuromuscular Junction Disorders. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 1536-1563.	0.8	6
49	2269-PUB: Early Attrition from a Randomized Lifestyle Modification Protocol. Diabetes, 2019, 68, .	0.6	0
50	Measuring Clinical Treatment Response in Myasthenia Gravis. Neurologic Clinics, 2018, 36, 339-353.	1.8	51
51	Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. Neurologic Clinics, 2018, 36, 293-310.	1.8	24
52	Lambert-Eaton Myasthenic Syndrome. Neurologic Clinics, 2018, 36, 379-394.	1.8	80
53	Diagnosis of Myasthenia Gravis. Neurologic Clinics, 2018, 36, 261-274.	1.8	50
54	Treatment of Myasthenia Gravis. Neurologic Clinics, 2018, 36, 311-337.	1.8	135

#	Article	IF	Citations
55	Fifty Key Publications on Myasthenia Gravis and Related Disorders. Neurologic Clinics, 2018, 36, xiii-xvii.	1.8	0
56	An instrumented timed up and go in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2018, 57, 503-506.	2.2	13
57	Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2018, 20, 49-59.	0.7	7
58	Review process for IVIg treatment. Neurology: Clinical Practice, 2018, 8, 429-436.	1.6	9
59	Toxic myopathies. Current Opinion in Neurology, 2018, 31, 575-582.	3.6	28
60	Update on Inclusion Body Myositis. Current Rheumatology Reports, 2018, 20, 52.	4.7	7
61	Congenital Myasthenic Syndromes: a Clinical and Treatment Approach. Current Treatment Options in Neurology, 2018, 20, 36.	1.8	34
62	Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics, 2018, 15, 995-1005.	4.4	49
63	Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial. Physical Therapy, 2017, 97, 20-31.	2.4	9
64	Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. Journal of Immunology, 2017, 198, 1460-1473.	0.8	92
65	Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid Î±-Glucosidase in Pompe Patients Co-administered with Alglucosidase Î±. Molecular Therapy, 2017, 25, 1199-1208.	8.2	36
66	Outcome measures in the idiopathic inflammatory myopathies. Neurology, 2017, 89, 20-21.	1.1	2
67	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
68	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.9	754
69	Less is More in Diabetic Neuropathy Diagnosis: Comparison of Quantitative Sudomotor Axon Reflex and Skin Biopsy. Journal of Clinical Neuromuscular Disease, 2017, 19, 5-11.	0.7	4
70	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	3.8	115
71	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	5.6	391
72	A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization. Trials, 2016, 17, 428.	1.6	20

#	Article	IF	Citations
73	Amifampridine phosphate (Firdapse^{Â®}) is effective and safe in a phase 3 clinical trial in LEMS. Muscle and Nerve, 2016, 53, 717-725.	2.2	51
74	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiology of Aging, 2016, 47, 218.e1-218.e9.	3.1	40
75	Compromised fidelity of Bâ€cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2016, 3, 443-454.	3.7	39
76	Targeting protein homeostasis in sporadic inclusion body myositis. Science Translational Medicine, 2016, 8, 331ra41.	12.4	99
77	Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology, 2016, 87, 2067-2068.	1.1	2
78	Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123.	1.1	49
79	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
80	Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Statistics in Medicine, 2015, 34, 1134-1149.	1.6	23
81	The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiology of Aging, 2015, 36, 1766.e1-1766.e3.	3.1	16
82	Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients. Neuromuscular Disorders, 2015, 25, 625-631.	0.6	12
83	Peripheral Neuropathies. , 2015, , 857-888.		1
84	A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 345-352.	1.7	26
85	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
86	A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics, 2015, 12, 455-460.	4.4	23
87	Long-Term Neurological Outcomes in West Nile Virusâ€"Infected Patients: An Observational Study. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1006-1012.	1.4	85
88	Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 727-734.	1.8	14
89	Motor Neuron Disease. Neurologic Clinics, 2015, 33, xiii-xiv.	1.8	0
90	Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 889-908.	1.8	48

#	Article	IF	Citations
91	The Dilemma of the Clinical Trialist in Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 937-947.	1.8	7
92	Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 735-748.	1.8	78
93	Primary Lateral Sclerosis. Neurologic Clinics, 2015, 33, 749-760.	1.8	53
94	Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.8	30
95	Safety of Aerobic Exercise in People With Diabetic Peripheral Neuropathy: Single-Group Clinical Trial. Physical Therapy, 2015, 95, 223-234.	2.4	56
96	Sporadic inclusion body myositis. Current Opinion in Neurology, 2014, 27, 591-598.	3.6	18
97	Acquired Immune Demyelinating Neuropathies. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 1241-1260.	0.8	8
98	Pompe Disease. Neurologic Clinics, 2014, 32, 751-776.	1.8	104
99	A Pattern Recognition Approach to Patients with a Suspected Myopathy. Neurologic Clinics, 2014, 32, 569-593.	1.8	70
100	Myopathies. Neurologic Clinics, 2014, 32, xiii-xiv.	1.8	1
101	Idiopathic Inflammatory Myopathies. Neurologic Clinics, 2014, 32, 595-628.	1.8	82
102	Toxic Myopathies. Neurologic Clinics, 2014, 32, 647-670.	1.8	42
103	Distal Myopathies. Neurologic Clinics, 2014, 32, 817-842.	1.8	34
104	Inclusion Body Myositis. Neurologic Clinics, 2014, 32, 629-646.	1.8	76
105	Diabetic Neuropathy Part 1. Neurologic Clinics, 2013, 31, 425-445.	1.8	81
106	Diabetic Neuropathy Part 2. Neurologic Clinics, 2013, 31, 447-462.	1.8	22
107	Cryptogenic Sensory Polyneuropathy. Neurologic Clinics, 2013, 31, 463-476.	1.8	24
108	Multifocal Motor Neuropathy, Multifocal Acquired Demyelinating Sensory and Motor Neuropathy, and Other Chronic Acquired Demyelinating Polyneuropathy Variants. Neurologic Clinics, 2013, 31, 533-555.	1.8	39

#	Article	IF	Citations
109	Nutritional Neuropathies. Neurologic Clinics, 2013, 31, 477-489.	1.8	83
110	North America and South America (NA-SA) neuropathy project. International Journal of Neuroscience, 2013, 123, 563-567.	1.6	24
111	Preface. Neurologic Clinics, 2013, 31, xi-xii.	1.8	0
112	Inclusion Body Myositis. Current Neurology and Neuroscience Reports, 2013, 13, 321.	4.2	53
113	Chronic Inflammatory Demyelinating Polyneuropathy. Current Treatment Options in Neurology, 2013, 15, 350-366.	1.8	53
114	Guillain-BarrÃ© Syndrome. Current Treatment Options in Neurology, 2013, 15, 338-349.	1.8	14
115	Guillain-BarrÃ© Syndrome and Variants. Neurologic Clinics, 2013, 31, 491-510.	1.8	260
116	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
117	Leg Amyotrophic Diplegia. Journal of Clinical Neuromuscular Disease, 2013, 15, 7-12.	0.7	13
118	Facial Onset Sensorimotor Neuronopathy Syndrome. Journal of Clinical Neuromuscular Disease, 2012, 14, 7-10.	0.7	16
119	Idiopathic Inflammatory Myopathies. Seminars in Neurology, 2012, 32, 227-236.	1.4	37
120	Inclusion Body Myositis. Seminars in Neurology, 2012, 32, 237-245.	1.4	43
121	Phase II trial of methotrexate in myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 23-28.	3.8	15
122	Benefit of Qigong Exercise in Patients With Fibromyalgia: A Pilot Study. International Journal of Neuroscience, 2012, 122, 657-664.	1.6	50
123	Correspondence Regarding: TDP-43 Proteinopathy and Motor Neuron Disease in Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29. Journal of Neuropathology and Experimental Neurology, 2011, 70, 96-97.	1.7	9
124	Autonomic nerve function in adult patients with cyclic vomiting syndrome. Neurogastroenterology and Motility, 2011, 23, 439-443.	3.0	44
125	Idiopathic inflammatory myopathies. Journal of Neuroimmunology, 2011, 231, 32-42.	2.3	47
126	Ocular Myasthenia Gravis in an Academic Neuro-Ophthalmology Clinic: Clinical Features and Therapeutic Response. Journal of Clinical Neuromuscular Disease, 2011, 13, 46-52.	0.7	48

#	Article	IF	Citations
127	Retrospective Chart Review of Duloxetine and Pregabalin in the Treatment of Painful Neuropathy. International Journal of Neuroscience, 2011, 121, 521-527.	1.6	11
128	Clinical findings in MuSKâ€antibody positive myasthenia gravis: A U.S. experience. Muscle and Nerve, 2010, 41, 370-374.	2.2	216
129	A Review: The Use of Rituximab in Neuromuscular Diseases. Journal of Clinical Neuromuscular Disease, 2010, 12, 91-102.	0.7	16
130	Idiopathic Inflammatory Myopathies. Frontiers of Neurology and Neuroscience, 2009, 26, 126-146.	2.8	15
131	Abnormalities in the Autonomic Nerve Function Profile of Adults with Cyclic Vomiting Syndrome. American Journal of Gastroenterology, 2009, 104, S488.	0.4	3
132	Exercise intolerance associated with a novel 8300t>C mutation in mitochondrial transfer RNAlys. Muscle and Nerve, 2006, 34, 437-443.	2.2	9
133	cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Medical Science Monitor, 2004, 10, BR191-7.	1.1	32
134	Human immunodeficiency virusâ€“associated polymyositis: A longitudinal study of outcome. Arthritis and Rheumatism, 2003, 49, 172-178.	6.7	97
135	Very Late-Onset Friedreich Ataxia Despite Large GAA Triplet Repeat Expansions. Archives of Neurology, 2000, 57, 246.	4.5	50
136	Benign Monomelic Amyotrophy of the Lower Extremity. Journal of Clinical Neuromuscular Disease, 2000, 1, 181-185.	0.7	8
137	Cauda equina syndrome as the isolated presentation of sarcoidosis. Journal of Neurology, 2000, 247, 573-574.	3.6	14
138	Identification of a Novel Mutation in Patients with Medium-Chain Acyl-CoA Dehydrogenase Deficiency. Molecular Genetics and Metabolism, 2000, 69, 259-262.	1.1	15
139	Peripheral nerve injury after brief lithotomy for transurethral collagen injection. Urology, 2000, 56, 669.	1.0	23
140	Phenytoin-Induced Dermatomyositis: Case Report and Literature Review. Journal of Child Neurology, 1998, 13, 577-580.	1.4	16
141	Reversible dementia and chorea in a young woman with the lupus anticoagulant. Neurology, 1996, 46, 1599-1603.	1.1	34
142	Critical Illness Polyneuropathy in Adolescence. Journal of Child Neurology, 1995, 10, 409-411.	1.4	13
143	Blood-based Biomarkers for Amyotrophic Lateral Sclerosis. , 0, , 105-120.		4